Skip to main content
Premium Trial:

Request an Annual Quote

Danaher to Split Stock, Buy Back Shares

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher today said that its board of directors has approved a two-for-one split of its common stock, as well as a share repurchase program.

The diversified firm, which owns businesses including AB Sciex, Molecular Devices, and Leica Microsystems, said the split will be effected through a stock dividend payable on June 11 to shareholders of record on May 25. Shareholders will receive one additional share of common stock for each share of common stock held.

Following the consummation of the stock split, Danaher also will pay a cash dividend of $.02 per share on July 30 to shareholders of record on June 25.

In addition, Danaher's board of directors has authorized the repurchase of up to 10 million shares of the firm's common stock, or 20 million shares post-split. It said that this repurchase plan replaces a repurchase program approved in April 2005.

In Wednesday afternoon trade on the New York Stock Exchange, shares of Danaher were up 3 percent at $86.66.

Danaher currently has around 324.7 million shares outstanding and a market capitalization of roughly $28.1 billion.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.